Perspective Therapeutics unveils updated corporate presentation with clinical progress

Perspective Therapeutics, Inc.

Updated presentation highlights [212Pb]VMT-α-NET Phase 1/2a for neuroendocrine tumors with sustained anti-tumor activity and tolerability.
Melanoma program [212Pb]VMT01 Phase 1/2a trial for metastatic melanoma includes TEAE safety data and trial design.
PSV359 Phase 1/2a trial targets FAP-α expression on tumor and stroma for multiple cancers.
Company describes pre-targeting platform and on-demand supply chain for regional radiopharmaceutical delivery.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.